About this trial
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Eligibility criteria
Qualifiers
Age 18 years or older
Unilateral symptomatic stroke due to ischemia. (Note: Bilateral acute stroke is permitted if the stroke that is contralateral to the index stroke is asymptomatic).
Motor deficits in the acutely affected UE, defined as a Shoulder Abduction and Finger Extension (SAFE) score ≤ 8 out of 10 points20,61 (i.e., excluding full or nearly full motor strength in both shoulder abduction and finger extension) within 48 to 96 hours of stroke onset (or time last known well).
Provision of signed and dated informed consent form within 24 to 96 hours of stroke onset, (or time last known well). Note: Participant is considered "enrolled" upon starting TMS (at least one stimulation is delivered) or starting study-specific MRI pulse sequence (at least one MRI beep occurs)
Disqualifiers
UE injury or conditions on paretic side that limited use prior to the stroke
Legally blind
Dense sensory loss on paretic side indicated by a score of 2 on NIHSS sensory item
Unable to abduct the shoulder or extend the fingers of the non-paretic UE on verbal command
Trial design
Treatments tested in this trial
- Transcranial Magnetic Stimulation (TMS)
Treatment groups
Sponsors and collaborators
Yale University
Lead sponsor
University of California, Los Angeles
Collaborator
University of Auckland, New Zealand
Collaborator
Medical University of South Carolina
Collaborator
University of Cincinnati
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator